KANAZAWA UNIVERSITY
- Country
- 🇯🇵Japan
- Ownership
- Private
- Established
- 1949-05-31
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.kanazawa-u.ac.jp
Clinical Trials
114
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (113 trials with phase data)• Click on a phase to view related trials
Selective Removal of Endometriotic Lesions Using CUSA Clarity in Ovarian Endometriomas
- Conditions
- Ovarian EndometriomaEndometriosis
- First Posted Date
- 2025-10-10
- Last Posted Date
- 2025-10-10
- Lead Sponsor
- Kanazawa University
- Target Recruit Count
- 10
- Registration Number
- NCT07215130
- Locations
- 🇯🇵
Kanazawa University Hospital, Kanazawa, Ishikawa-ken, Japan
SGLT2 Inhibitor Versus Sulfonylurea on Type 2 Diabetes With NAFLD
- Conditions
- Non-alcoholic Fatty Liver Disease
- Interventions
- First Posted Date
- 2016-01-07
- Last Posted Date
- 2021-07-02
- Lead Sponsor
- Kanazawa University
- Target Recruit Count
- 40
- Registration Number
- NCT02649465
- Locations
- 🇯🇵
Kanazawa University Graduate School of Medical Sciences, Kanazawa, Ishikawa, Japan
Phase I of Vorinostat-Iressa Combined Therapy on Resistance by BIM Polymorphysim in EGFR Mutant Lung Cancer
- First Posted Date
- 2014-05-30
- Last Posted Date
- 2018-02-05
- Lead Sponsor
- Kanazawa University
- Target Recruit Count
- 12
- Registration Number
- NCT02151721
- Locations
- 🇯🇵
Nagoya University Graduate School of Medicine, Nagoya, Aichi, Japan
🇯🇵Institute of Biomedical Research and Innovation Hospital, Kobe, Hyogo-ken, Japan
🇯🇵Kanazawa University Hospital, Kanazawa, Ishikawa, Japan
Clinical Trial of Autologous Adipose Tissue Derived Stromal Cell Therapy for Ischemic Heart Failure
- Conditions
- Ischemic Heart Failure
- First Posted Date
- 2012-10-18
- Last Posted Date
- 2017-08-18
- Lead Sponsor
- Kanazawa University
- Target Recruit Count
- 6
- Registration Number
- NCT01709279
- Locations
- 🇯🇵
Kanazawa University Hospital, Kanazawa, Ishikawa, Japan
Efficacy and Safety of Ursodeoxycholic Acid (UDCA) Added to the DPP-4 Inhibitor in People With Type 2 Diabetes and Chronic Liver Diseases
- Conditions
- Type 2 Diabetes MellitusChronic Liver Disease
- Interventions
- First Posted Date
- 2011-04-18
- Last Posted Date
- 2011-04-18
- Lead Sponsor
- Kanazawa University
- Target Recruit Count
- 20
- Registration Number
- NCT01337440
- Locations
- 🇯🇵
Internal medicine, Kanazawa university hospital, Kanazawa, Ishikawa, Japan
- Prev
- 1
- 2
- Next
News
Zimmer Biomet Receives World's First PMDA Approval for Iodine-Treated Hip Replacement System
Zimmer Biomet received Japan PMDA approval for the iTaperloc Complete and iG7 Hip System, marking the world's first approved orthopedic implants with iodine technology designed to inhibit bacterial adhesion and prevent biofilm formation.